Arecor Limited, the biopharmaceutical company, has signed a formulation study partnership with Eli Lilly and Company (Lilly).   Under this agreement, Arecor will use its proprietary formulation technology platform Arestat to develop a differentiated, thermostable formulation of one of Lilly’s proprietary products intended for self-administration. The thermostable formulation will allow greater convenience of use of the product by patients, whilst maintaining its integrity.   Lilly will fund ...